Journal
LEUKEMIA & LYMPHOMA
Volume 49, Issue 1, Pages 36-41Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428190701684518
Keywords
amyloidosis; multiple myeloma; restrictive cardiomyopathy; stem cell transplantation; troponin T
Categories
Ask authors/readers for more resources
The efficacy of stem cell transplantation in amyloidosis largely is determined by treatment-related mortality rates (range, 11-25%). Appropriate patient selection is essential to avoid this high mortality rate. Among 271 patients undergoing stem cell transplantation, troponin T was a powerful predictor of treatment-related mortality. Patients with troponin T levels of 0.06g/L or higher had a day-100 all-cause mortality rate of 28%. Patients with troponin T levels less than 0.06g/L had a day-100 all-cause mortality rate of 7% (P0.001). Troponin T levels should be measured in all patients before transplantation. Those with troponin T levels exceeding 0.06g/L should be considered for less toxic therapies until the clinically optimal use of stem cell transplantation is better defined by randomized clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available